{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:43:16Z","timestamp":1793720596667,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Youth Fund of the First Affiliated Hospital of Zhengzhou University","award":["700203"],"award-info":[{"award-number":["700203"]}]},{"name":"the Youth Fund of the First Affiliated Hospital of Zhengzhou University","award":["70200"],"award-info":[{"award-number":["70200"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U1704177, 81871811"],"award-info":[{"award-number":["U1704177, 81871811"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Youth Project of Medical Science and Technology of Henan Provincial and Ministerial Joint Projects","award":["11551"],"award-info":[{"award-number":["11551"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Dermatomyositis (DM) positive with anti-melanoma differentiation-associated gene 5 (anti-MDA5-DM) is a systemic autoimmune disease with high mortality. This study aimed to explore the risk factors of death in anti-MDA5-DM and validate a prediction model for all-cause mortality in anti-MDA5-DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We conducted a retrospective study using a single-centre cohort of patients with newly onset anti-MDA5-DM from June 1, 2018 to August 31, 2021. Patients were divided into four groups according to baseline ground-glass opacity (GGO) score: Group A, GGO\u2009\u2264\u20091; Group B, 1\u2009&lt;\u2009GGO\u2009\u2264\u20092; Group C, 2\u2009&lt;\u2009GGO\u2009\u2264\u20093; Group D, GGO\u2009&gt;\u20093. The primary outcome was death during the follow-up. Secondary outcomes included death within 3, 6, 12 months, severe infection, and remission during the first 12 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 200 patients were included in the study. Based on multivariable Cox regression, the prognostic factors at baseline were identified as CRP\u2009&gt;\u20095\u00a0mg\/L, serum ferritin (SF)\u2009&gt;\u2009600ng\/ml, positive anti-Ro52 antibody, prophylactic use of compound sulfamethoxazole (SMZ Co), four-category GGO score: GGO\u2009\u2264\u20091, 1\u2009&lt;\u2009GGO\u2009\u2264\u20092, 2\u2009&lt;\u2009GGO\u2009\u2264\u20093, GGO\u2009&gt;\u20093. The final mortality of four groups was 16.4, 22.2, 48.5, 92.0%, respectively. Compared with Group A, the Hazards Ratio (HR) of Group B was 1.408, (p\u2009=\u20090.408), HR of Group C was 3.433 (p\u2009=\u20090.005), HR of Group D was 4.376 (p\u2009=\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>GGO score is a reliable predictor for risk stratification in anti-MDA5-DM and may provide guidance for individualized managements of patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02827-x","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T12:02:01Z","timestamp":1689940921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ground-glass opacity score predicts the prognosis of anti-MDA5 positive dermatomyositis: a single-centre cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Lijun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"issue":"3","key":"2827_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/ard.2003.006122","volume":"63","author":"M Fathi","year":"2004","unstructured":"Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63(3):297\u2013301.","journal-title":"Ann Rheum Dis"},{"key":"2827_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fmed.2020.00363","volume":"7","author":"Y Li","year":"2020","unstructured":"Li Y, Gao X, Li Y, Jia X, Zhang X, Xu Y, et al. Predictors and mortality of Rapidly Progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: a Series of 474 patients. Front Med (Lausanne). 2020;7:363.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"2827_CR3","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193\u2013200.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2827_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","volume":"147","author":"Y Hamaguchi","year":"2011","unstructured":"Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147(4):391\u20138.","journal-title":"Arch Dermatol"},{"issue":"9","key":"2827_CR5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51(9):1563\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2827_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/1346-8138.14092","volume":"45","author":"J Li","year":"2018","unstructured":"Li J, Liu Y, Li Y, Li F, Wang K, Pan W, et al. Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: a systematic meta-analysis. J Dermatol. 2018;45(1):46\u201352.","journal-title":"J Dermatol"},{"issue":"1","key":"2827_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-021-01705-8","volume":"16","author":"Q Yang","year":"2021","unstructured":"Yang Q, Li T, Zhang X, Lyu K, Wu S, Chen Y, et al. Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients. Orphanet J Rare Dis. 2021;16(1):58.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2827_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13613-018-0433-3","volume":"8","author":"C Vuillard","year":"2018","unstructured":"Vuillard C, Pineton de Chambrun M, de Prost N, Guerin C, Schmidt M, Dargent A, et al. Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a french multicenter retrospective study. Ann Intensive Care. 2018;8(1):87.","journal-title":"Ann Intensive Care"},{"issue":"5","key":"2827_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1684\/ejd.2019.3634","volume":"29","author":"SI Motegi","year":"2019","unstructured":"Motegi SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol. 2019;29(5):511\u20137.","journal-title":"Eur J Dermatol"},{"key":"2827_CR10","doi-asserted-by":"crossref","unstructured":"You H, Wang L, Wang J, Lv C, Xu L, Yuan F et al. Time-dependent changes in RPILD and mortality risk in anti-MDA5 + DM patients: a cohort study of 272 cases in China. Rheumatology (Oxford). 2022.","DOI":"10.1093\/rheumatology\/keac450"},{"issue":"1","key":"2827_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/rheumatology\/keab305","volume":"61","author":"W Wu","year":"2021","unstructured":"Wu W, Xu W, Sun W, Zhang D, Zhao J, Luo Q, et al. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study. Rheumatology (Oxford). 2021;61(1):230\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"2827_CR12","doi-asserted-by":"crossref","unstructured":"Wang LM, Yang QH, Zhang L, Liu SY, Zhang PP, Zhang X et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatology (Oxford). 2021.","DOI":"10.1093\/rheumatology\/keab928"},{"issue":"7","key":"2827_CR13","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","volume":"60","author":"A Xu","year":"2021","unstructured":"Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford). 2021;60(7):3343\u201351.","journal-title":"Rheumatology (Oxford)"},{"key":"2827_CR14","doi-asserted-by":"crossref","unstructured":"Xu YT, Zhang YM, Yang HX, Ye LF, Chen F, Lu X et al. Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease. Rheumatology (Oxford). 2022.","DOI":"10.1093\/rheumatology\/keac229"},{"issue":"4","key":"2827_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10067-015-2866-5","volume":"34","author":"J Zou","year":"2015","unstructured":"Zou J, Guo Q, Chi J, Wu H, Bao C. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients. Clin Rheumatol. 2015;34(4):707\u201314.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2827_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14397595.2017.1318468","volume":"28","author":"Y Fujiki","year":"2018","unstructured":"Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol. 2018;28(1):133\u201340.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"2827_CR17","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno F, Diaz Del Campo P, Trallero-Araguas E, Ruiz-Rodriguez JC, Castellvi I, Rodriguez-Nieto MJ, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50(4):776\u201390.","journal-title":"Semin Arthritis Rheum"},{"key":"2827_CR18","doi-asserted-by":"publisher","first-page":"33226","DOI":"10.1038\/srep33226","volume":"6","author":"T Li","year":"2016","unstructured":"Li T, Guo L, Chen Z, Gu L, Sun F, Tan X, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. 2016;6:33226.","journal-title":"Sci Rep"},{"issue":"3","key":"2827_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, Tacrolimus, and Cyclophosphamide in interstitial lung Diseases accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol. 2020;72(3):488\u201398.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2827_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated interstitial lung disease. N Engl J Med. 2019;381(3):291\u20133.","journal-title":"N Engl J Med"},{"issue":"12","key":"2827_CR21","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57(12):2114\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2827_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14397595.2021.1906505","volume":"32","author":"S Takanashi","year":"2022","unstructured":"Takanashi S, Kaneko Y, Takeuchi T. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: a literature review. Mod Rheumatol. 2022;32(1):231\u20137.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"2827_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"4","key":"2827_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2214\/ajr.169.4.9308447","volume":"169","author":"EA Kazerooni","year":"1997","unstructured":"Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169(4):977\u201383.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"2827_CR25","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571\u20136.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2827_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","volume":"23","author":"S Sato","year":"2013","unstructured":"Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23(3):496\u2013502.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"2827_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13075-021-02606-8","volume":"23","author":"L Huang","year":"2021","unstructured":"Huang L, Fu Q, Ye Y, Lin Y, Yan Q, Chen S. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res Ther. 2021;23(1):232.","journal-title":"Arthritis Res Ther"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02827-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02827-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02827-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T12:05:50Z","timestamp":1689941150000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02827-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2827"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02827-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (2022-KY-0427).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}